CA-LEVITASBIO
LevitasBio, Inc., a premier end-to-end sample processing and cellular analysis provider to the life sciences market, announced the hiring of Dominique Remy-Renou as its Senior Vice President of Global Commercial Operations of LevitasBio Europe BV, and the appointment of Greg Herrema to its Board of Directors.
The addition of two Life Sciences veterans bring decades of biotech industry expertise and a history of proven success to LevitasBio’s already strong leadership team and board.
Dominique Remy-Renou, Senior Vice President of Global Commercial Operations, LevitasBio Europe BV
Ms. Remy-Renou has over 30 years’ experience leading, building, developing and managing global field operations in the life sciences tools industry. Her stellar career includes:
- CEO at Genomic Vision, a French provider of Molecular Combing.
- VP Commercial Operations Europe at Fluidigm where she led the introduction of disruptive technologies into the single-cell European market.
- President and General Manager at Pacific Biosciences where she led the penetration of the sequencing market with their proprietary Long Read sequencing technology.
- Senior Director of Marketing Europe at Applied Biosystems.
“I am thrilled to join the tremendous team at LevitasBio,” said Dominique Remy-Renou, newly appointed Senior VP of Global Commercial Operations for LevitasBio Europe BV. “Our transformative technology is a gamechanger in the cellular processing and characterization market. I look forward to increasing our field presence and helping to drive our commercial success.”
Greg Herrema, Board of Directors
A Harvard Business School MBA graduate, Mr. Herrema joins the LevitasBio board with extensive experience managing large, global, high tech businesses across a diverse range of products, services, and end markets. His ability to develop and implement growth strategies and his track record for driving commercial performance will bring welcome insights and strategic thinking to LevitasBio. Greg’s roles in Thermo Fisher Scientific included responsibility for multiple multi-billion dollar revenue businesses:
- President of the $8Bn revenue Fisher Scientific and Fisher Healthcare Channels, the industry-leading distribution business for laboratory and clinical supplies.
- President of the $1Bn revenue Bioscience business (life science reagents, bioprocess production, and research chemicals), where he was the business champion for the $16Bn acquisition of Life Technologies.
- President of the $3Bn revenue Analytical Instruments business where he completed over 20 acquisitions including the $2.1Bn acquisition of Dionex.
“I am excited to join the LevitasBio board of directors. LevitasBio's innovative approach to the label-free separation of cells at the single-cell level is highly differentiated and their product portfolio offers significant customer value. I look forward to playing a role in enabling LevitasBio's success.”
“We couldn’t be happier to welcome Dominique and Greg to the C-Suite and board of directors, respectively,” stated Martin Pieprzyk, CEO of LevitasBio. “We look forward to their contributions as we become the industry standard in cellular analysis.”
LevitasBio —True Biology Begins Here
Our mission is to advance science and human health by providing researchers with new and powerful methods of cellular analysis. LevitasBio delivers the first truly novel approach to cellular analysis in 30 years. Our proprietary label-free levitation technology enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, or modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221128005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference15.1.2026 01:40:00 CET | Press release
Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studiesHaving secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this yearSamsung Bioepis plans to add one novel therapeutic candidate in clinical study every year Samsung Epis Holdings (KRX: 0126Z0) today shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114206458/en/ Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings "2026 is a mon
Most Delivered Light-Entry Jet Cessna Citation M2 Gen2 With Garmin Autothrottles Enters Into Service, Bringing Greater Control and Precision to Pilots14.1.2026 20:30:00 CET | Press release
The Cessna Citation M2 Gen2 with Garmin Autothrottles recently entered into service. Certified by the Federal Aviation Administration in October 2025, the integration of Garmin’s Autothrottle system in the Citation M2 Gen2 further supports the most delivered light-entry jet’s capabilities by bringing greater control and precision to pilots. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114646844/en/ Most delivered light-entry jet Cessna Citation M2 Gen2 with Garmin Autothrottles enters into service, bringing greater control and precision to pilots (Photo Credit: Textron Aviation). The Cessna Citation M2 Gen2 is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. “We continue to invest in our products to provide customers with the best aviation experience in the world," said Lannie O’Bannion, senior vice president, Sales & Marketing. “The M2 Gen2 leads its segment as the most delivered
TwentyTwo Real Estate and Farallon Capital Complete €761 Million Investment in Isemia, a €1.2bn Healthcare Real Estate Company Created With emeis14.1.2026 18:30:00 CET | Press release
TwentyTwo Real Estate, an independent European real estate investment and management firm, announces the completion, alongside Farallon Capital, of a €761 million investment that led to the creation of Isemia (www.isemiabyemeis.com), a leading healthcare real estate company holding a €1.2 billion portfolio of assets operated by emeis. The transaction represents a significant milestone in TwentyTwo Real Estate’s long-term investment strategy focused on healthcare and operational living real estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260114262830/en/ Fachklinik Schömberg Isemia comprises 68 high-quality assets across France, Germany and Spain, with a balanced mix of nursing homes (48%) and clinics (52%). The portfolio benefits from strong fundamentals and resilient operating performance. All properties will continue to be operated by emeis under long-term lease agreements, ensuring continuity of care for residents
AI’s Water Demand to Surge Nearly 130% by 2050 – New Research Shows How to Build a Water-Secure AI Economy14.1.2026 16:00:00 CET | Press release
Analysis finds AI could add 30 trillion liters of annual water demand, but targeted reuse and digital infrastructure investments can substantially offset demand and protect communities The rapid global expansion of artificial intelligence is set to drive a 129% increase in water demand across the AI value chain by 2050, according to new research by Xylem (NYSE: XYL) and Global Water Intelligence (GWI). Watering the New Economy: Managing the Impacts of the AI Revolution provides the most comprehensive assessment to date of how AI is reshaping global water use. It also highlights practical ways to meet that demand while strengthening water security for communities. Spending on AI is forecast to approach $2 trillion in 2026,1 accelerating infrastructure build-out worldwide. By the middle of the century, this expansion is projected to add 30 trillion liters of water demand, annually, fueled by a surge in power generation (~54% of the increase), semiconductor fabrication (~42%), and data ce
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave™ for Autonomous Testing Platforms14.1.2026 16:00:00 CET | Press release
Agentic Test Automation Pioneer Caps Record-Breaking Year of Growth and "AI-Based Engineering Solution of the Year" Honors Forrester has named ACCELQ a Leader in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025. This marks the third consecutive Wave in which ACCELQ has been recognized as a Leader. Notably, this evaluation placed strong emphasis on generative AI innovation and real-world customer adoption. ACCELQ received the highest scores for both capabilities and vision and was the only platform to be recognized as a Customer Favorite, earning a "double halo" for exceptional customer endorsement. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113112861/en/ ACCELQ recognized as a Leader and Customer Favorite in The Forrester Wave™️: Autonomous Testing Platforms, Q4 2025, validating its agentic, GenAI-embedded testing vision. According to the Forrester report, ACCELQ received the highest score among all evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom